摘要
目的 评价新型抗胆碱药物托特罗定治疗膀胱过度活动症的有效性和安全性。 方法 采用随机、双盲、双模拟、平行对照的方法对 2 0 7例膀胱过度活动症患者进行托特罗定与奥昔布宁的对比研究 ,服药方法每日 2次 ,每次托特罗定 2mg或奥昔布宁 5mg。 结果 治疗 6周后 ,托特罗定组 (10 3例 ) 2 4h平均排尿次数减少 (3.0± 3.4)次 ,其中尿失禁患者的平均尿失禁次数减少 (1.5± 1.8)次 ;奥昔布宁组 (10 4例 )治疗后 2 4h平均排尿次数减少 (4 .6± 6 .4)次 ,平均尿失禁次数减少(2 .4± 2 .1)次 ,两组间差别无显著性意义 (P >0 .0 5 )。托特罗定组患者副作用发生率 6 6 .9% ,其中口干为 5 5 .3% ;而奥昔布宁组发生率为 87.5 % ,口干为 76 .9% ,两组间差别有显著性意义 (P <0 .0 5 )。 结论 托特罗定是治疗膀胱过度活动症的有效药物 ,疗效与奥昔布宁相同 ,但不良反应明显低于奥昔布宁。
Objective To evaluate the efficacy and tolerability of tolterodine in patients with an overactive bladder. Methods A randomized,double-blind,double-simulant,parallel-controlled,multicentric study was carried out in 207 patients with bladder overactivity,patients received either tolterodine (2 mg twice daily)or oxybutynin (5 mg twice daily). Results After 8 weeks of treatment,the mean frequency of micturition decreased 3.0±3.4 times and 4.6±6.4 times in those receiving tolterodine (n=103) and oxybutynin(n=104),respectively.Among those with urge incontinence,the mean number of incontinence episodes decreased 1.5±1.8 times and 2.4±2.1 times,respectively,in those receiving tolterodine and oxybutynin.The effect of tolterodine and oxybutynin on these two micturition variables was statistically equivalent.In the tolterodine group,the total incidence of adverse event was 66.9% and the incidence of dry mouth,the most common adverse,was 55.3%.While in the oxybutynin group,the incidences were 87.5% and 76.9% respectively.The incidences of adverse events and dryness were significantly lower in those on tolterodine than in those on oxybutynin. Conclusions Tolterodine 2 mg twice daily had the equivalent efficacy on patients with overactive bladder as compared to oxybutynin 5 mg twice daily,and the adverse events of tolterodine were lower than oxybutynin.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2001年第4期217-219,共3页
Chinese Journal of Urology
